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Background: The discovery of novel anti-viral restriction factors illuminates unknown aspects of innate sensing and
immunity. We identified RNA-associated Early-stage Anti-viral Factor (REAF) using a whole genome siRNA screen for
restriction factors to human immunodeficiency virus (HIV) that act in the early phase of viral replication.
Results: We observed more than 50 fold rescue of HIV-1 infection, using a focus forming unit (FFU) assay, following
knockdown of REAF by specific siRNA. Quantitative PCR was used to show that REAF knockdown results in an
increase of early and late reverse transcripts which impacts the level of integration. REAF thus appears to act at an
early stage of the viral life cycle during reverse transcription. Conversely when REAF is over-expressed in target cells
less infected cells are detectable and fewer reverse transcripts are produced. Human REAF can also inhibit HIV-2
and simian immunodeficiency virus (SIV) infection. REAF associates with viral nucleic acids and may act to prevent
reverse transcription.
Conclusions: This report firmly places REAF alongside APOBECs and SAMHD1 as a potent inhibitor of HIV
replication acting early in the replication cycle, just after cell entry. We propose that REAF is part of an anti-viral
surveillance system destroying incoming retroviruses. This novel mechanism could apply to invasion of cells by any
intracellular pathogen.Background
The extent of the cellular armoury against viral infection
is becoming increasingly appreciated. In particular hu-
man immunodeficiency virus (HIV) must overcome
many cellular obstacles on its replication pathway to the
nucleus. Once HIV enters the cytoplasm its genomic
RNA is reverse transcribed by the virally encoded re-
verse transcriptase (RT), resulting in hybrid RNA:DNA
intermediates. The RNase H activity of RT degrades the
RNA from these hybrids resulting in single stranded (ss)
DNA from which the second DNA strand is synthesised.
Immediately upon initiation the process of reverse tran-
scription is susceptible to members of the apolipoprotein
B mRNA-editing, enzyme-catalytic, polypeptide-like
(APOBEC) family by inducing deoxycytidine to deoxyur-
idine mutations in the nascent DNA [1]. In primary* Correspondence: a.mcknight@qmul.ac.uk
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SAMHD1 degrades dNTPs which are required for effi-
cient reverse transcription [2-4]. Two other factors p21
and PAF1 act at an early stage however their mechanism
of action is not yet understood [5,6]. Once reverse tran-
scription is complete the pre-integration complex (PIC)
containing the double stranded (ds)DNA is then formed
and integrated into the genome of the host cell. This
process is inhibited by the TRIM28 (KAP1)/SETDB1
complex [6,7]. Once the provirus is integrated the late
phase of the replication cycle begins with the production
of viral proteins [8]. Finally, a plasma membrane located
restriction factor tetherin/BST-2/CD317, prevents viruses
from leaving the cell at the late budding stage of the life
cycle [9].
Using a whole genome siRNA screen [6], we identified
RPRD2 (here called RNA-associated Early-stage Anti-
viral Factor; REAF) as a potential restriction factor.
REAF is a protein of previously unknown function. Our
data suggest that it acts at an early post-entry stage ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reverse transcription.
Characterising the action of a novel restriction factor
reveals molecular details of HIV replication and innate
host immunity and more importantly may lead to novel
therapeutics for HIV and possibly other viral infections.
Results
REAF inhibits HIV and SIV infection and occurs at an early
post-entry stage of replication
The full details of our genome wide siRNA screen that
identified new cellular anti-viral restriction factors acting at
the early stages of HIV-1 replication have previously been
published [6]. Briefly, HeLa-CD4 cells were transfected with
an siRNA library targeting 19,121 human genes and thenA
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Figure 1 REAF inhibits HIV and SIV infection and occurs at an early p
following REAF siRNA knockdown compared with CB control. REAF is shown
detectable in all experiments. Tubulin (57 kDa) is added as a loading control.
with HIV-189.6, HIV-2CBL-23, SIVAGM (African Green Monkey; TYO-1), SIVMAC (Maca
post infection (pi) indicates that REAF rescues viral replication. Results are sho
(C) siRNA knockdown of REAF results in enhanced HIV-1 RT products – early a
copies are normalised to genomic GAPDH and presented per million cells. Reschallenged with an HIV-189.6R pseudovirus carrying a GFP
reporter gene (HIV-1 gag/pol/tat and rev, HIV-2 MCR
Env). Gene knockdowns resulting in enhanced viral replica-
tion were chosen for further validation. For REAF valid-
ation, 4 siRNAs targeting different regions of REAF mRNA
were initially tested to eliminate the possibility of off-target
effects. 3/4 siRNAs showed the same phenotype of rescue
(Additional file 1). A single siRNA was chosen for all subse-
quent experiments requiring silencing of REAF (siRNA
REAF 4; Figure 1A, target sequence in Additional file 1).
To quantify the ability of REAF to rescue infection,
HeLa-CD4 cells were challenged with dual tropic wild
type HIV-189.6 following siRNA knockdown. HIV-1 infec-
tion was strongly rescued following REAF silencing (>50
fold); from 6.9 × 102 to 3.5 × 104 focus forming unitsost-entry stage of replication. (A) Western blot of HeLa-CD4 cell lysate
as three bands at 80, 130 (faint) and 220 kDa, but not all bands are
(B) 72 hr post siRNA knockdown of REAF, HeLa-CD4 cells are challenged
que; 32H) and SIVSM (Sooty Mangabey; B670). p24 immunostaining 48 hr
wn as fold change compared with a non-targeting control siRNA (CB).
nd late (0–8 hr pi) and (D) proviral DNA (Alu-gag, 2–48 hr pi). HIV-1 DNA
ults are mean ± s.d. of a representative experiment performed in duplicate.
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FFU data; Additional file 2). To determine if this anti-viral
effect was restricted to HIV-1 we also tested for activity
against HIV-2CBL-23 and various strains of simian im-
munodeficiency virus (SIV); African Green Monkey
(TYO-1, SIVAGM), Macaque (32H, SIVMAC) and Sooty
Mangabey (B670, SIVSM). We observed significant rescue
of all viruses between 15–126 fold (Fold change cf. CB
control; Figure 1B, Raw FFU data; Additional file 2).
There are multiple stages in the virus life cycle vulner-
able to attack by cellular restriction factors. To gain insight
into the action of REAF anti-viral activity we determined
the point in the viral life cycle which is impeded. Cells were
challenged with HIV-189.6 after REAF was down modu-
lated. Using real time quantitative PCR (qPCR) the initi-
ation and completion of negative strand strong-stop DNA
(−sssDNA; early) and full length (late) RT products were
measured at various time points after infection (Figure 1C).
Knockdown of REAF enhanced both early and late tran-
script levels within 1–2 hours of viral challenge, indicating
that the reverse transcription process is targeted. An Alu-
PCR assay subsequently found an increase in the amount
of detectable integrated provirus (Figure 1D). This is prob-
ably a result of more available full length viral cDNA tran-
scripts and correlates with a block by REAF during the
reverse transcription process.
Over-expression of REAF confers restriction which is viral
route of entry dependent
To confirm that REAF protein is responsible for the res-
cue of viral replication observed following siRNA knock-
down, over-expression experiments were also performed.
To reconstitute the restriction, an EGFP-tagged expres-
sion construct for REAF was generated. Over-expression
of REAF-EGFP was confirmed by Western blot analysis
(Figure 2A). Similar to endogenous REAF protein
(Figure 1A) the REAF-EGFP expression construct also pro-
duced three bands. As expected, the over-expression of
REAF-EGFP was able to inhibit viral replication following
challenge with HIV-189.6. In contrast to other REAF siRNA
knockdown experiments, here HeLa-CD4 cells were pre-
treated with siRNA targeting the 3’ untranslated region
(UTR) of REAF in order to degrade endogenous REAF be-
fore transfection of REAF-EGFP and pEGFP-C3 (empty
vector) expression constructs (Western blot and target se-
quence data for REAF 3’UTR siRNA shown in Additional
file 3). The inhibition by exogenous REAF in these experi-
ments is weak compared to the >50 fold increase observed
following siRNA knockdown. This is due to only poor
(<10%) transfection efficiencies being achieved given the
large size of the REAF-EGFP construct (Additional file 4).
In spite of these technical difficulties, we were able to ob-
serve an inhibition of viral replication with REAF-EGFP
over-expression by p24 immunostaining (Figure 2B). Toconfirm this inhibition, the levels of HIV-189.6 DNA were
measured in HeLa-CD4 cells similarly treated with REAF
3’UTR siRNA. After transfection of REAF-EGFP and chal-
lenge with HIV-189.6, the amount of RU5 and late reverse
transcripts was measured 8 hr pi, showing a 1.7 and 1.5
fold decrease respectively in cells expressing REAF-EGFP
compared with pEGFP-C3 alone (Figure 2C). Given the
poor transfection efficiency described above, these observa-
tions correlate with the qPCR results following siRNA
knockdown of REAF, where a 4.5 fold increase in late tran-
scripts is measured at the same time point (Figure 1C).
We previously reported that the Lv2 post entry restric-
tion to HIV can be dependent on the envelope mediated
route of entry [10-13]. To determine whether the anti-
viral activity of REAF is route of entry dependent, HIV-
189.6Δenv/VSV-G pseudotyped virus was used to challenge
HeLa-CD4 cells following REAF knockdown by siRNA.
The 89.6Δenv construct contains the full length 89.6 gen-
ome, with a stop codon in the Env ORF, so these pseudo-
typed virions still produce p24 following integration and
thus infection was measured by p24 immunostaining as
above. In contrast to HIV-189.6, no rescue of infected foci
was observed after challenge with HIV-189.6Δenv/VSV-G
pseudotypes (Figure 2D). VSV-G triggers entry by
clathrin-mediated endocytosis through a ubiquitously
expressed glycolipid. These results suggest that REAF-
mediated restriction of HIV-189.6 is circumvented by a
VSV-G mediated route of entry.
REAF interacts with viral nucleic acids.
As stated above, the function of REAF is previously un-
known thus giving no clues as to its possible mode of
interaction with viral replication. The timing of its inhib-
ition during the reverse transcription phase of the viral
life cycle suggested that REAF may interact with nucleic
acids. To investigate this possibility, and determine if en-
dogenous REAF associates with RNA, immunoprecipita-
tion using oligo (dT) magnetic beads was performed.
Oligo (dT) beads were incubated with HeLa-CD4 lysate
prior to isolation of the bead-bound RNA/protein. As
controls, cell lysates were additionally treated with either
DNase or a titration of an RNaseA/RNaseH cocktail be-
fore the beads were added. The immunoprecipitated
protein was then analysed by Western blotting for the
presence of REAF. Results for the untreated sample
show that REAF protein was specifically precipitated
when oligo (dT) was used as bait (Figure 3A). Following
DNase treatment, REAF is no longer detected suggesting
that REAF may associate with complexes containing
DNA. RNaseA specifically cleaves ssRNA, while RNaseH
degrades DNA:RNA hybrid complexes. REAF was still
found to be associated with the oligo (dT) beads in sam-
ples treated with RNase, and surprisingly the amount of
REAF appeared to increase at higher concentrations of
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Figure 2 Over-expression of REAF confers restriction which is viral route of entry dependent. (A) Over-expression of REAF restricts early
HIV-1 DNA production. HEK 293 T cells were transiently transfected with pEGFP-C3 or REAF-EGFP and the Western blot probed with α-GFP
antibody. Transfection of REAF-EGFP results in expression of REAF (110, 160 and 250 kDa including EGFP tag (30 kDa). Endogenous REAF was
knocked out of HeLa-CD4 cells using siRNA targeting its 3’ UTR. (B) Infected cells were measured following transient over-expression of REAF-EGFP
or pEGFP-C3 and challenge with HIV-189.6. Results are shown as FFU/ml and are mean ± s.d. of a representative experiment performed in duplicate.
(C) Transient over-expression of REAF-EGFP in HeLa-CD4 cells results in decreased RU5 and late RT products 8 hr post challenge with HIV-189.6. HIV-1
DNA copies are normalised to genomic GAPDH and presented per million cells. Results are mean ± s.d. of a representative experiment performed in
duplicate. (D) Restriction by REAF is dependent upon viral route of entry. HIV-189.6Δenv was pseudotyped with VSV-G envelope and used to challenge
HeLa-CD4 cells following REAF siRNA knockdown. p24 immunostaining was used to detect FFU compared with HIV-189.6. Results are shown as FFU/ml
and are mean ± s.d. of a representative experiment performed in duplicate.
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degraded, additional binding sites for REAF are revealed,
resulting in the increased association observed. It could
be argued that the REAF binding observed was due to
the protein binding directly to the beads used. To elim-
inate this samples were also analysed for a positive con-
trol (poly(A) binding protein; PABP) which binds to the
poly(A) tail of mRNA. As expected this protein is no
longer detected in the RNase treated samples confirming
that REAF binds through an RNA bridge and not dir-
ectly to the beads themselves. It is also unlikely that the
loss of REAF binding in the DNase treated samples is
due to digest of oligo (dT) by DNase, as the enzyme isphysically removed from the lysate before addition of
the oligo (dT) beads. The success of this removal was
confirmed by the presence of PABP in DNase treated
samples. The negative control (GAPDH) confirms the
oligo(dT) beads are binding specifically to proteins asso-
ciated with nucleic acids. Thus the results showing that
REAF associates (directly or indirectly) with polyadeny-
lated RNA and DNA are compatible with our hypothesis
that it can potentially target incoming viral genomes or
RNA:DNA intermediates or double stranded (ds)DNA
products of reverse transcription.
To investigate this further, HEK 293 T cells were
transfected with vectors expressing either REAF-EGFP
AC
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Figure 3 REAF interacts with viral nucleic acids. (A) Oligo d(T) immunoprecipitation of HeLa-CD4 cell lysate shows that REAF associates with
captured RNA. Cell lysate was treated with DNase or titrated RNaseA/H before incubation with oligo (dT) beads. Immunoprecipitated protein was
analysed by Western blotting and probed for REAF along with positive (PABP) and negative (GAPDH) controls. (B) HEK 293 T cells were transiently
transfected with pEGFP-C3 or REAF-EGFP and the Western blot probed with α-REAF antibody. Endogenous and exogenous REAF are detectable
in input samples (lanes 1 and 2) and following IP of samples transfected with pEGFP-C3 (endogenous REAF; lanes 7 and 8) or REAF-EGFP
(endogenous and exogenous REAF; lane 9 and 10) with α-REAF antibody, but not after IP with IgG alone (lanes 3–6). (C) The amount of RU5 or
late HIV-1 DNA qPCR product is quantified and normalised to input and IgG negative controls. Endogenous REAF associates with viral nucleic
acids and this is enriched in the cells over-expressing REAF-EGFP.
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DNA. All samples were lysed and incubated with either
rabbit IgG (control) or α-REAF antibody conjugated pro-
tein A/G beads before immunoprecipitation (IP). Spe-
cific isolation of REAF protein by IP was confirmed by
Western (Figure 3B). Following extensive washing, total
RNA was isolated from the bead-bound complexes and
reverse transcription (RT)-qPCR, using viral specific
primers (RU5 and late), was performed. All results were
normalised to input and the negligible level of qPCR
products detected in IgG IP samples. Following this ana-
lysis, in cells only expressing endogenous REAF (trans-
fected with pEGFP-C3), a 3.8 and 5.5 fold enrichment of
viral RU5 and late transcripts respectively was measured
compared with samples that were not transfected with
virus (first half of Figure 3C). A further enrichment inboth RU5 (16 fold) and late (32 fold) viral cDNA was
seen following over-expression of REAF-EGFP (second
half of Figure 3C), indicating a specific association of
REAF protein and viral nucleic acids. To confirm the
RT-qPCR results, a standard PCR was performed on the
isolated cDNA and terminated at a non-saturating num-
ber of amplification cycles. These PCR products were
run on a 4% agarose gel and visually confirm the re-
ported qPCR results (Additional file 5).
The low amounts of recovered viral nucleic acids in this
assay require initial transfection of viral DNA as previously
published [14]. It must be noted therefore, that the viral
RNA is thus not being delivered to the cell as in normal in-
fection and reverse transcription is not taking place. Never-
theless our results suggest an association of REAF with
viral nucleic acids. Since the restriction acts in the early
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with RNA:DNA intermediates or dsDNA products of HIV
reverse transcription, either directly or indirectly targeting
them for degradation.
REAF is downregulated in response to HIV-1 infection and
restriction requires reverse transcription
One characteristic of viral restriction factors is that
viruses evolve a means of bypassing them. We tested
whether HIV infection affected the levels of REAF ex-
pression in cells. RNA was extracted from HeLa-CD4
cells at various time points after challenge with HIV-
189.6. RT-qPCR of these samples showed that REAF
mRNA is unaffected following viral infection (Figure 4A).
REAF protein levels however, decrease in the initial
hours following challenge with HIV-1, recovering to pre-
infection levels by 2 hours (Figure 4B and C). The level
of REAF protein does not decrease in the presence ofA
C
Figure 4 REAF is downregulated in response to HIV-1 infection and re
mRNA following challenge with HIV-189.6. qPCR results from analysis of cDN
downregulated following challenge with HIV-189.6. Treatment with MG132
as a loading control. Only the lower band of REAF (80 kDa) is shown – not
AZT (100 nM), challenge with HIV-189.6 no longer causes depletion of REAFthe proteasome inhibitor MG132 suggesting that this
protein is targeted to conventional proteosomal degrad-
ation (Figure 4B). It is possible that the down modula-
tion observed is mediated by the virus in an attempt to
facilitate the establishment of infection, similar to that
seen for APOBEC3G and SAMHD1 [15,16]. Thus HIV-1
may have evolved a means of mitigating the effects of
REAF using cellular proteosomal degradation pathways.
Alternatively the degradation of REAF may be a by-
product of the restriction process and occur after it asso-
ciates with its viral target as a part of the normal cellular
process of viral restriction. Further experimentation is
required to determine the trigger for the loss of REAF
post viral challenge.
To further characterise this virus-REAF interplay we in-
vestigated whether reverse transcription itself plays a role.
A similar time course of infection was performed on
HeLa-CD4 cells that had been pre-treated with AZTB
striction requires reverse transcription. (A) Time course of REAF
A are normalised to β-actin mRNA levels. (B) REAF protein levels are
(10 μM) prevents the degradation of REAF protein. Tubulin is included
all bands are detected in all experiments. (C) Following treatment with
at 1 hr pi. GAPDH is included as a loading control.
Marno et al. Retrovirology 2014, 11:3 Page 7 of 9
http://www.retrovirology.com/content/11/1/3(Figure 4C). In contrast to untreated cells, REAF was not
degraded in the presence of AZT, suggesting that initiation
of reverse transcription is required to trigger degradation
of REAF. We hypothesise that REAF interacts either with
the products of reverse transcription (RNA:DNA interme-
diates or dsDNA) directly or indirectly to restrict replica-
tion and is degraded in the proteasome.
Discussion
Our results demonstrate that REAF is a new potent anti-
HIV/SIV restriction factor. The timing of both the re-
striction to viral replication and the virus’ potential
counterattack supports our model that REAF acts upon
a viral nucleic acid target at an early post-entry stage of
infection, before the viral genome reaches the nucleus.
The phenotype of a restriction factor is most readily
observed for REAF following its knockdown in HeLa-
CD4 cells by siRNA. These experiments consistently
show >50 fold rescue of viral titre for HIV-1 and even
greater for HIV-2. Interestingly, REAF is also able to act
against other non-human retroviruses, suggesting a
common viral target. This restriction is confirmed by
over-expression of REAF-EGFP, resulting in a decrease
in the amount of both FFU/ml and HIV-1 DNA ampli-
fied by qPCR compared with cells transfected with
empty vector (pEGFP-C3) and challenged with virus.
REAF is similar to already identified restriction factors
TRIM5α, APOBECs and SAMHD1 because it acts at an
early post-entry stage of infection. An increase in the
earliest detectable form of RT products (−sssDNA) is
seen within the first 1–2 hours following viral challenge
in cells down modulated for REAF, and this difference
grows steadily with time. The accumulation of full
length HIV-1 DNA transcripts results in higher levels of
integration, which will impact the ability of the virus to
spread more quickly through multiple rounds of infec-
tion. Of course we cannot rule out that REAF may add-
itionally block a step after reverse transcription. The
apparent ability of REAF to bind DNA, along with our
results showing higher rescue of infected cells relative to
RT products in REAF knockdown cells, would be con-
sistent with this hypothesis.
The viral target itself probably involves nucleic acid
recognition: indeed we demonstrate that REAF associ-
ates with viral nucleic acids. However we cannot be sure
whether the interaction is direct or indirect. The inter-
action with nucleic acids suggests that the surveillance
mechanism may have implications for the invasion of
cells by any RNA virus.
A characteristic of restriction factors of HIV-1 is that
viruses evolve to mitigate their effects. Here we observed
that REAF is destroyed after viral infection. As early as
1 hour after viral challenge, REAF protein levels are de-
pleted in HeLa-CD4 cells, yet REAF mRNA levelsremain constant throughout infection. Depletion of
REAF is prevented in the presence of proteasomal in-
hibitor suggesting that REAF is specifically targeted for
degradation through cellular proteasomal pathways. The
early time frame for this virally induced degradation co-
incides with the point in the viral life cycle restricted by
REAF. It is possible that HIV-1 targets cellular REAF
precisely to prevent inhibition of its critical initiation of
reverse transcription. The hypothesis that REAF targets
viral replication after the initiation of reverse transcrip-
tion is supported by the abrogation of REAF protein
down modulation in the presence of the AZT. However
we cannot exclude that REAF is being destroyed by a
cellular programme activated after it recognises its target
as part of the restriction process.
In recent years, several cellular factors with the ability
to suppress HIV-1 replication early in the viral life cycle
have been described. It would therefore not be surprising
if the virus has evolved to counteract this onslaught.
Studies so far have shown that APOBEC and tetherin, as
well as the recently discovered SAMHD1, are antago-
nised by viral proteins HIV-1 Vif, Vpu and HIV-2 Vpx
respectively [9,15,17]. The potential of a viral antagonist
for REAF has not yet been determined. The destruction
of REAF is similar to that of SAMHD1 which is targeted
for cellular proteasomal degradation by HIV-2 Vpx [15].
Conclusions
The mechanism of REAF anti-viral activity shares simi-
larities with known restriction factors APOBEC, tetherin
and SAMHD1 and is an important new addition to the
cellular armoury against viral infection. It is vital to
understand the interaction of HIV and innate cellular re-
striction factors as they represent a relatively untapped
source of therapeutic potential. Small molecule pharma-
ceuticals capable of regulating a pathway of interest to
enhance the interaction between a viral protein and its
cellular antagonist may be a valuable approach.
Methods
Cells
Culture of HEK 293 T, HeLa-CD4 and C8166 cells and
their optimal culture conditions have been described
previously [12,18].
Plasmids and virus production
The REAF-EGFP expression plasmid was generated by
PCR amplifying the open reading frame from HeLa-CD4
cDNA. The vector used was pEGFP-C3 (Clontech). The
infectious molecular clone for HIV-189.6 was obtained
from the Centre for AIDS Research (NIBSC, UK). Plas-
mid construct HIV-189.6Δenv was generated from the
HIV-189.6 molecular clone using overlap extension PCR.
Clones were confirmed by plasmid sequencing (Source
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request. Virus stocks were prepared from infectious full-
length or pseudotyped HIV clones by polyethylenimine
(Polysciences) or Lipofectamine 2000 (Invitrogen) trans-
fection of HEK 293 T cells. HIV-2CBL-23 and SIV stocks
were grown in C8166 cells.
Preparation of protein lysates
Prior to analysis on SDS-PAGE gels, cell pellets were lysed in
ice cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1%
NP-40, 0.25% sodium deoxycholate) containing protease in-
hibitor cocktail (Roche Applied Sciences) and 5 mM of so-
dium fluoride, β-glycerophosphate and sodium orthovanadate.
Western blot and immunoprecipitations
SDS-PAGE separated proteins, immobilised on nitrocellu-
lose membrane (Novex) were detected with the primary
rabbit polyclonal antibody against REAF (RbpAb-RPRD2),
rabbit pAb-GAPDH, rabbit pAb-PABP or rat pAb-tubulin
(Abcam) followed by corresponding horseradish pero-
xidise-conjugated goat α-rabbit/rat antibody (Abcam).
Proteins were visualised using a chemiluminescence kit
(ECL/ECL Prime, GE Healthcare).
Oligo (dT) immunoprecipitation
Prior to oligo (dT) addition, control samples were treated
with DNase (10U) or increasing amounts of an RNaseA/H
cocktail (250-2500U RNaseA, 20U RNaseH) and incubated
at 37°C for 15 min. DNase (DNA-free™ Kit; Invitrogen) was
physically removed from the appropriate sample according
to manufacturer’s instructions. Ribonucleoprotein properties
of REAF were then investigated by mixing lysates prepared
as above with oligo (dT) magnetic beads (Invitrogen). After
15 min at 4°C the oligo (dT)-protein complexes were washed
extensively with lysis buffer and TE. The complex was eluted
into 1× PAGE loading buffer and analysed by Western blot.
Viral RNA IP and RT-qPCR analysis
Immunoprecipitation of viral RNA was performed as previ-
ously reported with slight modifications [14]. Briefly, HEK
293 T cells were transfected with either pEGFP-C3 or
REAF-EGFP and HIV-189.6 molecular clone DNA using Li-
pofectamine 2000 (Invitrogen). Cells were washed 2× with
ice cold PBS then 2× with ice cold swelling buffer (25 mM
HEPES, 1.5 mM MgCl2, 85 mM KCl, pH 8.0) and lysed in
ice cold lysis buffer (25 mM HEPES, 1.5 mM MgCl2,
85 mM KCl, 0.02% NP-40, 1% Triton X-100, pH 8.0) con-
taining RNaseOUT (500U/ml, Invitrogen), protease inhibitor
cocktail (Roche Applied Sciences) and 10 mM of sodium
fluoride, sodium pyrophosphate, β-glycerophosphate, and so-
dium orthovanadate. After centrifugation, the lysate was in-
cubated with 2U of DNase (Ambion) for 5 min at 37°C and
pre-cleared with Protein A/G-coupled rabbit IgG beads for
30 min at 4°C. One tenth of the volume was kept for totalcellular RNA input, one tenth for Western blotting input
and the rest mixed with Protein A/G-coupled REAF Ab
beads and incubated for 1 hr at 4°C. The bead bound com-
plexes were washed 2× with lysis buffer, 2× with wash buffer
(25 mM HEPES, 1.5 mM MgCl2, 85 mM KCl, 0.25% Triton
X-100, pH 8.0) containing 0.1U/ml RNaseOUT, 2× in wash
buffer supplemented with 0.4 M NaCl followed by 2 washes
with wash buffer supplemented with 0.1U/ml RNaseOUT
and 0.1% v/v SDS. An aliquot of the complex was kept for
Western blotting while the rest was incubated with DNase
for 10 min followed by two phenol:chloroform:isoamyl alco-
hol (50:49:1) and one chloroform extraction. After precipita-
tion with ethanol and glycogen carrier (Ambion), the RNA
pellet was resuspended in DEPC-treated water and reverse
transcribed using Superscript III First Strand Synthesis Sys-
tem (Invitrogen) according to manufacturer’s instructions.
The resulting cDNA was used in qPCR analysis with primers
for RU5 and late HIV-1 DNA as previously described [19].
Primers are available upon request. This qPCR was repeated
in a standard PCR machine for a non-saturating number of
amplification cycles. These PCR products were resolved on a
4% agarose gel for visual confirmation.
siRNA transfection and infection with replication
competent virus
HeLa-CD4 cells were seeded at 2.5 × 104 cells/well in 24-
well plates. siRNA transfection (30nM) was performed
using HiPerfect (QIAGEN) according to the manufac-
turer’s instructions. 72 hr after siRNA transfection, cells
were challenged with virus (MOI 0.2) for up to 5 hr. Infec-
tion was assessed up to 48 hr by intracellular p24 staining
or qPCR analysis. When required, reverse transcriptase
inhibitor AZT (100 μM) and proteasomal inhibitor
MG132 (10 μM) were added 1 hr before infection.
In situ immunostaining for p24 antigen
Infected cells were fixed with cold (−20°C) methanol:
acetone (1:1), washed with PBS then immunostained for
p24 using mouse anti-HIV-1 p24 monoclonal antibodies
EVA365 and 366 (NIBSC, UK) (1:50) or anti-SIV p27
monoclonal antibodies (1:500) (to detect SIV infected
cells), as previously described [20]. Infected cells were
blue (regarded as foci of infection (FFU/ml)) and quanti-
tated by light microscopy.
First round Alu-PCR
DNA was extracted at various time points after infection
with the QIAamp DNA Blood Mini Kit (QIAGEN). Inte-
grated HIV-1 DNA was measured by nested PCR, as
previously described [19].
qPCR for HIV-1 DNA
The isolated DNA was subjected to qPCR to determine the
number of early (negative strand strong stop DNA,
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http://www.retrovirology.com/content/11/1/3-sssDNA), RU5 and late (gag) transcripts, normalised for cell
number by genomic GAPDH as previously described [19].
cDNA synthesis and mRNA analysis
Total HeLa-CD4 RNA was extracted using an RNeasy
Plant Mini Kit (QIAGEN) and cDNA was synthesised with
Superscript III First Strand Synthesis System (Invitrogen),
according to manufacturer’s instructions. The cDNA pro-
duced was subjected to qPCR as previously described [19].
Primer sequences used to determine REAF mRNA levels
are available upon request.
Additional files
Additional file 1: Validation of REAF siRNA. (A) The four siRNAs from
the original screening pool were individually tested at 30nM using the
same protocol as the siRNA screen [6]. For REAF, 3/4 siRNAs enhanced
virus replication. (B) Target sequence of the 4 REAF siRNAs tested. REAF 4
siRNA was used in all subsequent knockdown experiments except where
stated.
Additional file 2: siRNA knockdown of REAF rescues viral
replication. siRNA knockdown of REAF rescues infection of HeLa-CD4
cells by HIV-189.6, HIV-2CBL-23, SIVAGM (African Green Monkey; TYO-1),
SIVMAC (Macaque; 32H) and SIVSM (Sooty Mangabey; B670) infection
compared with a non-targeting siRNA control (CB). Raw data is shown as
FFU/ml and are mean ± s.d. of a representative experiment performed in
duplicate.
Additional file 3: Validation of REAF 3’UTR siRNA. (A) Western blot of
HeLa-CD4 cell lysate following REAF 3’UTR siRNA knockdown compared
with CB control. Only the 80 and 220 kDa bands are detectable. GAPDH
(36 kDa) is added as a loading control. (B) Target sequence of REAF 3’UTR
siRNA.
Additional file 4: Transfection efficiency of REAF-EGFP compared to
pEGFP-C3. HeLa-CD4 cells transfected with REAF-EGFP or pEGFP-C3
empty vector. Cells were analysed by immunofluorescence 24 hr post
transfection.
Additional file 5: REAF associates with viral nucleic acids. RU5 and
late HIV-1 DNA were amplified by standard RT-PCR from RNA isolated
from viral RNA IP. PCR program was terminated at a non-saturating
amplification cycle and reaction products were run on a 4% agarose gel
for visual confirmation. RU5 and late PCR products are detectable in input
samples (lanes 1 and 3) and following IP of either endogenous (lane 9) or
exogenous (REAF-EGFP) (lane 11) REAF with α-REAF antibody, but not
after IP with IgG alone (lanes 5 and 7).
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